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The effects of intraperitoneal calcitriol on calcium and parathyroid
hormone. Parathyroid suppression by intraperitoneal calcitriol
(l,25(OH)2D3) during peritoneal dialysis. The purpose of this study was
to determine if parathyroid hormone (PTH) suppression could be
achieved by increasing calcium mass transfer (Ca MT) with high
dialysate Ca (4 mEq/liter) or via intraperitoneal (i.p.) I ,25(OH)2D3 in
patients undergoing continuous ambulatory peritoneal dialysis. Eleven
patients were dialyzed for two months with standard Ca dialysate (3.5
mEq/liter) followed by two months with 4.0 mEq/liter Ca, then by three
months of i.p. l,25(OH)2D3. During the latter period, patients were
randomized to groups whose dialysate contained either 3.5 mEq/liter or
4.0 mEq/liter Ca. We found that 4.0 mEq/liter Ca dialysate more than
doubled Ca MT (37 17 mg/day to 84 6mg/day) leading to a modest
fall (P < 0.05) in PTH levels (84 5.5% of controls). Ionized calcium
levels did not change. With i.p. I ,25(OH)2D3, however, ionized calcium
rose significantly (P < 0.001) leading to a decline in PTH levels to 53.9
7.9% of control values. Serum I ,25(OH)2D3 levels rose from unde-
tectable to 47.7 7.2 pg/dl (normal range 20 to 35). These studies
indicate that increasing Ca MT using a 4.0 mEq/liter Ca dialysate leads
to a small reduction in PTH concentrations. On the other hand, i.p.
l,25(OH)2D3 is well absorbed into the systemic circulation, raises
ionized calcium levels, and leads to a marked suppression of PTH.
Thus, i.p. I ,25(OH)2D3 may be a simple and effective means to suppress
secondary hyperparathyroidism in patients undergoing CAPD.
We have previously shown a variable effect of CAPD on
parathyroid hormone (PTH) levels despite substantial removal
of this polypeptide and maintenance of ionized calcium (1Ca)
levels at the upper limits of normal with oral calcium supple-
ments [1]. At these higher concentrations of 'Ca only 10 mg of
elemental calcium entered the patient per day from the dialy-
sate. It was conjectured that if PTH secretion could be sup-
pressed by increasing calcium mass transfer (Ca MT) via higher
dialysate concentrations of Ca, CAPD, unlike hemodialysis,
could serve as an additional avenue for PTH removal and
perhaps lower PTH levels [1]. More recently we have found
that intravenous (i.v.) l,25(OH)2D3 leads to a marked suppres-
sion of PTH levels in chronic hemodialysis patients [21. More-
over, i.v. l,25(OH)2D3 caused a greater suppression of PTH
than either oral I ,25(OH)2D3 or calcium supplements despite
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comparable levels of serum Ca. It was suggested that by
avoiding intestinal degradation, i.v. administration may result
in a heightened delivery of 1,25(OH)2D3 to peripheral target
tissues other than the intestine and allow a greater expression of
its biological effects.
Accordingly, these studies were designed to determine I) the
effect of an increased dialysate Ca (4.0 mEq/liter) and 2) the
potential benefits of the i.p. administration of 1,25(OH)2D3 on
PTH secretion.
Methods
Patient population
Eleven stable patients who had been treated with CAPD for
greater than six months were selected. There were five males
and six females whose ages ranged from 21 to 69 years (mean 52
years). Two had diabetes, two polycystic kidney disease, three
chronic glomerulonephritis, two hypertensive nephrosclerosis,
one interstitial nephritis and one congenital hypoplastic kid-
neys. All were virtually anuric with residual creatinine clear-
ance less than 1 mI/mm. No patient took oral vitamin D
preparations, corticosteroids or anticonvulsants. Oral calcium
was discontinued two weeks prior to the control period and
aluminum containing gels were prescribed at dosages to main-
tain phosphorus (P) levels between 4.5 to 5.5 mg/dl.
All patients underwent four 2-liter exchanges per day
(Inpersol, Abbott Laboratories, North Chicago, Illinois, USA).
Patients were instructed to vary the dextrose concentration in
the dialysate according to "dry weight". This usually resulted
in three-l.5% dextrose and one-4.25% dextrose exchanges per
day and remained generally constant throughout the study
periods. Written consent was obtained on all patients and the
research protocol was approved by the Human Studies Com-
mittee of Washington University.
Study design
The patients underwent CAPD for two months using standard
dialysate containing 3.5 mEq/liter of Ca and 1.5 mEq/liter of
magnesium (Mg). Following this control period, patients then
dialyzed for two months with a specially formulated dialysate
(Abbott Laboratories) identical to the control with the excep-
tion that the calcium concentration was increased to 4.0
mEq/liter. At the end of four months all patients began daily
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intraperitoneal I ,25(OH)2D. This vitamin D metabolite was
injected into the dialysate bag immediately prior to infusion for
the nocturnal eight hour dwell period. The initial dose of 0.5 g
was increased in an incremental fashion until the total serum
calcium (TCa) reached 10.5 to 11 mgldl or the maximum dose of
4 jgIday was reached. If the TCa was greater than 11.5 mg/dl or
if the calcium—phosphorus product was greater than 70 mg/dl,
I ,25(OH)2D was temporarily omitted from the solution. Be-
cause of variability in doses from subject to subject and
frequent adjustments in doses, a meaningful quantitative as-
sessment of i.p. I ,25(OH)2D3 administered is difficult. Most
patients were adequately maintained on 0.5 to 1.5 pg/day (range
0.5 to 2.0 gIday). Plasma levels of I ,25(OH)2D1 were measured
10 to 12 hours after the nocturnal infusion of this metabolite.
While starting i.p. l,25(OH)2D1, patients were also random-
ized to either continue with 4.0 mEq/liter Ca dialysate (N 5)
or revert to 3.5 mEq/liter Ca dialysate (N = 6). Serum TCa, 'Ca,
P. Mg, and PTH were measured every two weeks during the
first two periods and weekly during i.p. I ,25(OH)2D3. Calcium
mass transfer was calculated twice as previously described [I]
during each of the first two periods and thrice during the third.
Basically, Ca MT represents the difference between the net
amount of Ca removed per exchange from the amount instilled:
Mass transfer = dialysate Ca concentration instilled x
dialysate volume instilled — Dialysate Ca concentration
post exchange X dialysate volume post exchange.
A positive net transfer, therefore, represents the amount accru-
ing within the patient. The concentration of total calcium in the
unused dialysate bags was consistently found to be 7.0 or 8.0
mg/dl. The value used for the volume of instilled dialysate was
2050 ml.
Materials
.
$
Results
Total calcium and magnesium levels were determined by
atomic absorption spectrometry (Perkin—Elmer, Norwalk, Con-
necticut, USA, model 503). Ionized calcium was measured with
the Orion flow through electrode (Orion Research, Inc., Cam-
bridge, Massachusetts, USA, Model 5520). Phosphorus was
determined by routine laboratory methods adapted for the
Technicon Auto analyzer (Technicon instruments Corporation,
Tarrytown, New York, USA).
Radioimmunoassay of PTH was performed as previously
described in detail [3]. The antiserum, CH9, recognizes the
intact hormone, the mid-region, and the carboxy-terminal por-
tion of the PTH molecule and should be considered a mid-
region/C-terminal antiserum. Plasma levels of 1 ,25(OH)2D3
were measured as previously described [4]. The normal range
based on determinations in 33 normal subjects was 20 to 35
pg/mi with the minimal detectable 2 pg/mI. The inter-assay
coefficient of variation was 11.3% and intra-assay coefficient of
variation 6.2%.
Statistics
The values of parameters measured in individual subjects
were meaned for each study period. Group data, therefore,
reflects the mean of the mean SEM. The signed rank test was
employed for non-parametric analysis and paired t-test for
those values assuming a normal distribution.
During the control period the PTH levels were 202 71
jdEq/mI in association with an 'Ca of 4.72 0.09 mg/dl, P of
5.48 0.32 mg/dl and a Ca MT of 37.8 16.9 mg/day. With the
institution ofa4.0 mEq/liter Ca dialysate, the Ca MT more than
doubled to 84.1 6.2 mg/dl (P <0.01). Despite the improved
Ca MT, there were no changes in the 'Ca levels (4.79 0.07
mg/dl). A small, but statistically significant (P < 0.05, by signed
rank) fall in PTH levels to 84% of control values was observed.
There were no significant effects of a 3.5 mEq/Iiter Ca versus a
4.0 mEq/liter Ca dialysate on PTH or 'Ca levels during i.p.
I ,25(OH)2D3 and therefore all data were pooled. With the
addition of IP I ,25(OH)2D3 there was a more dramatic fall in
PTH to 53.9 7.9% of control values (P < 0.01) (Fig. 1).
Figure 2 depicts the serial mean values of iPTH and 'Ca levels
during each of the three study periods. Overall, there was little
change in either parameter during the first two study periods.
However, after one week of i.p. 1 ,25(OH)2D3, ionized calcium
levels began an ascent which reached a peak by the fifth week.
Thereafter, the 'Ca levels fluctuated in response to adjustments
of i.p. l,25(OH)2D3 dosages. During the first five weeks of i.p.
calcitriol, PTH fell steadily in response to rising 'Ca concentra-
tions and remained persistently lower than control values.
To further assess the contribution of increments in 'Ca on
iPTH suppression, the percent PTH (compared to control) was
plotted versus change in ionized calcium levels during the high
dialysate Ca and IP I ,25(OH)2D3 periods (Fig. 3). A highly
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Fig. I. The percent fall in PTH levels from baseline values during
treatment with 4.0 mEqlliter Ca dialysate and with the addition of i.p.
1,25(OH)2D. PTH levels fell by 15.6 5.6% with use of 4.0 mEq/liter
Ca dialysate (P < 0.05). The addition of lP I ,25(OH)2D3, however, led
to a 46.1 7.9% reduction in baseline PTH levels (P < 0.01).
Time, weeks
Fig. 2. Serial mean serum iPTH (•) and 'Ca (0) levels of the Ii study
patients. Verticle dashed lines separate the three study periods and the
horizontal dashed line denotes the upper limits of normal for ionized
calcium.
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Fig. 3. Mean increases in serum ionized calcium levels during the 4.0
mEqiliter calcium dialysate and IP I ,25(OH)2D3 periods (compared to
the mean of the control period) are plotted against the iPTH values (per
cent control). Each point represents the mean values of all study
patients at each sampling period. A highly significant (P < 0.001)
reciprocal relationship was determined with the Y-intercept approach-
ing 100% of control values. r = —0.762.
Dialysate
'Ca
mg/dl
TCa
mg/dl
P
--
mg/dl
Ca MT
mg/day
3.5 mEq/liter Ca 4.72 0.09 9.37 0.13 5.48 0.32 37 17
4.0 mEq/liter Ca 4.79 0.07 9.50 0.12 5.11 0.25 84 6b
i.p. l,25(OH),D3 5.31 0.09C 10.50 0.l7a 5.13 0.22 —5 21C
Student's t-test was employed for statistical analysis.
P < 0.001 i.p. D3 versus 3.5 and 4.0
b p < 0.01 4.0 versus 3.5
P < 0.01 4.0 versus i.p. D3
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significant (P < 0.001) inverse relationship was noted. More-
over, at no change in ionized calcium the Y-intercept of the
regression line was virtually 100% of the control value of iPTH.
The Y-intercept remained 100% if the change in 'Ca during i.p.
l,25(OH)2D3 alone was plotted on the abscissa. This finding
suggests that the major, if not sole effect of i.p. 1 ,25(OH)2D3 on
PTH suppression was due to increase in 'Ca concentrations.
The fall in PTH associated with a rise in 'Ca to 5.31 0.09
mgldl (P < 0.001) led to an overall decline in Ca MT to —5.0
20.8 mg/dl (P < 0.01) compared to 4.0 mEq/liter Ca dialysate,
NS compared to 3.5 mEq/liter dialysate). There was a slightly
higher Ca MT in the 4.0 mEq/liter Ca plus l,25(OH)2D3 group
than the 3.5 mEq/liter Ca plus I ,25(OH)2D3 group (11.7 mg/d vs.
—36.5 mg/day) but the small numbers precluded meaningful
analysis. There were no significant changes in serum Mg or P
levels during the course of the study. A summary of the
biochemical parameters of the patients during each study period
is shown in the table.
Serum I ,25(OH)2D3 rose from undetectable to 47.7 7.2
pgldl (normal range 20 to 35) during i.p. l,25(OH)2D3. In two
patients 2 g of i.p. I ,25(OH)2D3 was instilled and serum was
analyzed at 0, 2, 4, 6, and 8 hours, respectively, There was
rapid absorption with peak levels observed at two to four hours.
At eight hours the values for 1 ,25(OH)2D3 were still above the
normal range (Fig. 4).
No patient developed symptoms clearly attributable to
hypercalcemia during the study. The incidence of peritonitis
was once every 6.4 months during the entire study.
Discussion
There is considerable disagreement concerning the course of
renal osteodystrophy in patients undergoing peritoneal dialysis.
In part, this may be attributable to different medical regimens as
well as variable diagnostic criteria employed by each group.
Table 1. Biochemical parameters of the study patients
Calderaro et al [5] in 1980 reviewed the radiographic changes
of 28 patients on CAPD. All received 50,000 units of vitamin D3
per week and five were treated with oral 1,25(OH)2D3. None
apparently were on oral calcium supplements. They found
progression of subperiosteal resorption in 28% (suggesting
worsening osteitis fibrosa) and decreased resorption in 10.7% of
subjects. The authors stated that osteomalacia (the other major
form of renal osteodystrophy) may improve during CAPD. It is
of note that Calderaro utilized a 3.0 mEq/liter Ca dialysate and,
therefore, actually had a negative Ca MT of 50 mglday. A later
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may be low.
Following the institution of a dialysate Ca of 4.0 mEq/liter,
the Ca MT more than doubled, leading to a modest fall in PTH
levels. Although a high dialysate calcium may be of some use in
decreasing PTH, the changes are not dramatic. Moreover, as
larger doses of oral calcium carbonate are currently being
employed not only to suppress PTH but also to bind phospho-
rus [12, 13] (and thereby avoid aluminum containing gels and
the risk of aluminum toxicity), it would seem prudent to
Previous studies from this institution have shown that i.v.
maintain dialysate Ca at 3.5 mEq/liter.
1 ,25(OH)2D3 causes a dramatic fall in PTH levels in chronic
hemodialysis patients [2]. This metabolite also appears to be
Time, hours readily absorbable from peritoneal dialysate and effectively
Fig. 4. Serum levels of 1 ,25(OH)2D3 following the i.p. instillation of 2
pg of 1,25(OH)2D3 in 2 patients. Peak concentrations were detected at
suppresses PTH in patients on CAPD. Clearly, the major
mechanism is that of raising 'Ca. A close correlation between
2 to 4 hours with supranormal levels persisting at 8 hours. changes in IPTH and 'Ca levels as well as a Y-intercept very
near 100% the baseline iPTH level supports this concept. We
have previously shown that the Y-intercept was 80% in patients
report from the same group [6] determined that there was no undergoing hemodialysis and receiving i.v. l,25(OH)2D3 [2].
change or a worsening of the radiographic manifestations of This suggested that i.v. 1 ,25(OH)2D3 had both a direct and an
osteitis fibrosa in the majority of patients (14 of 17) during indirect effect of PTH secretion. This apparent discrepancy
CAPD. This was associated with a rising PTH level despite oral between the effects of i.v. versus i.p. l,25(OH)2D3 on PTH
I ,25(OH)2D3 therapy. Gokal et al [7], utilizing a 3.5 mEq/liter suppression merits further comment. Fifteen minutes following
Ca dialysate, however, reported significant improvement in the the intravenous administration of 2.0 jg of this metabolite,
histological manifestations of osteitis fibrosa in 11 of 20 paired levels of 400 to 500 pg/mI are attained [2]. By 30 minutes,
biopsy specimens. Oral calcium carbonate supplements and concentrations drop by approximately one—half but remain in
oral 1 ,25(OH)2D3 were employed to optimize calcium metabo- the 100 to 200 pglml range for at least eight hours. It is only after
lism. Of note, however, was the need to perform parathyroid- 24 hours that the levels fall below 100 pglml. The kinetics of the
ectomies in six patients because of severe secondary hyper- same amount of i.p. l,25(OH)2D3 are completely different.
parathyroidism. We have noted a variable effect of CAPD on There appears to be slow absorption resulting in peak levels in
PTH levels despite maintenance of'Ca levels at the upper limits two to four hours. Moreover, the peak levels are considerably
of normal [1]. Moreover, we have shown a close correlation lower than those noted with i.v. l,25(OH)2D3. Whether direct
between iPTH levels and bone fibrosis in CAPD patients [8]. suppression of PTH by 1,25(OH)2D3 is due to high peak levels
We [8] and others [5, 9] have found an overall improvement in (10 times normal), high continuous levels, or the route of
the degree of osteomalacia during CAPD. The above studies administration cannot be determined by these studies. How-
suggest that there is clearly a subgroup of patients on CAPD in ever, in vitro studies demonstrate a dose response curve for the
whom standard medical therapy does not control hyperpara- effects of I ,25(OH)2D3 on PTH secretion. Cantley et al [14]
thyroidism. Possibly the simplest method of suppressing PTH
would be to increase dialysate calcium and thereby improve Ca
found that incubation of cultured parathyroid cells for 48 hours
with physiological concentrations (10—" M) of 1,25(OH)2D3
MT. caused approximately a 40% decline in PTH secretion. Further
Parker and Nolph [10] found a large positive calcium balance
of 300 mg/d during CAPD. Although not reported by the
authors, one suspects that these patients were hypocalcemic
during the period of study. In a more detailed study, Blumen-
krantz et al [11] studied calcium balance in patients on CAPD.
He found a net dialysate uptake of calcium ranging from —22
mg/day to + 190 mg/day with a mean of 84 mg/day. These
patients were not on oral calcium supplements and no informa-
tion is given concerning the levels of 'Ca. We have previously
shown that with oral calcium supplementation sufficient to
achieve an 'Ca concentration at the upper limits of normal (4.9
0.1 mgldl), there is minimal positive Ca MT (9.9 mg/day) El].
suppression during incubation with media containing l0- and
l0— M I ,25(OH)2D3 was also noted. Furthermore, Silver,
Russell and Sherwood [15] have recently determined that these
dose dependent effects may be due to a decrease in the cellular
content of prepro-PTH mRNA.
In summary, an increased dialysate Ca leads to a modest
.
suppression of PTH levels despite a significant increase in Ca
MT. Intraperitoneal I ,25(OH)2D3, however, causes a marked
.
suppression of PTH via elevating 'Ca levels and may be an
effective agent to control osteitis fibrosa in patients undergoing
therapy with continuous ambulatory peritoneal dialysis.
Whether this form of therapy is superior to oral calcium and/or
oral vitamin D supplements awaits further study.
The current study revealed a net uptake of 37.8 16.9 mg/day
on patients off oral calcium supplements with an 'Ca of 4.72 Acknowledgments
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